Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AtG-153
- Development stage
- Preclinical
- Lead developer
- AtG Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AtG-153 is an orally available small molecule inhibitor developed by AtG Therapeutics. It targets Tumor Adaptation Factor 1 (TA-1), an enzyme overexpressed in aggressive, therapy-resistant tumors. By inhibiting TA-1, AtG-153 exploits adaptive synthetic lethality to selectively eliminate resistant cancer cells while sparing normal cells. The drug is currently in preclinical development for the treatment of advanced solid tumors, including renal cell carcinoma, colorectal cancer, and breast cancer.
02
Targets
TYMP (Thymidine phosphorylase)
Beyond the preview
Go deeper on AtG-153.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AtG-153.